Shares Magazine
233.70p+3.70 (+1.61%)07 Nov 2025, 08:52
Jump to:
Hutchmed (China) Limited Fundamentals
| Company Name | Hutchmed (China) Limited | Last Updated | 2025-11-07 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 859.339 m | Market Cap | £2.01 bn |
| PE Ratio | 5.66 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | $0.04 | EPS Growth (%) | -0.65 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0526 | Debt Equity Ratio | 0.0760 |
| Asset Equity Ratio | n/a | Cash Equity Ratio | n/a |
| Quick Ratio | 4.4142 | Current Ratio | 4.65 |
| Price To Book Value | 2.0986 | ROCE | 0 |
Hutchmed (China) Limited Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Hutchmed (China) Limited Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $97.00 m | $104.39 m | $84.67 m |
| Intangible Assets | 0 | 0 | 0 |
| Investments | $82.77 m | $48.41 m | $73.78 m |
| Total Fixed Assets | $207.64 m | $182.93 m | $189.56 m |
| Stocks | $50.40 m | $50.26 m | $56.69 m |
| Debtors | $167.74 m | $149.91 m | $127.17 m |
| Cash & Equivalents | $836.11 m | $886.34 m | $631.00 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $1.27 bn | $1.28 bn | $1.03 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $376.56 m | $403.03 m | $353.90 m |
| Creditors after 1 year | $125.78 m | $133.36 m | $38.67 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $502.34 m | $536.39 m | $392.57 m |
| Net assets | $771.85 m | $743.39 m | $636.87 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $87.16 m | $87.13 m | $86.48 m |
| Share Premium | $1.52 bn | $1.52 bn | $1.50 bn |
| Profit / Loss | -$1.11 m | $58.31 m | -$410.42 m |
| Other Equity | $759.93 m | $730.54 m | $610.37 m |
| Preference & Minorities | $11.92 m | $12.85 m | $26.50 m |
| Total Capital Employed | $771.85 m | $743.39 m | $636.87 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.08 | $0.07 | $0.04 |
| Debt-to-Equity | $0.08 | $0.07 | $0.04 |
| Assets / Equity | n/a | n/a | n/a |
| Cash / Equity | n/a | n/a | n/a |
| EPS | $0.04 | $0.13 | -$0.43 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $497,000.00 | $219.26 m | -$268.60 m |
| Cashflow before financing | -$30.17 m | $267.92 m | -$351.36 m |
| Increase in Cash | -$126.23 m | -$23.22 m | -$54.77 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $630.20 m | $838.00 m | $426.41 m |
| Cost of sales | $348.88 m | $384.45 m | $311.10 m |
| Gross Profit | $281.32 m | $453.55 m | $115.31 m |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | -$1.11 m | $58.31 m | -$410.42 m |
Hutchmed (China) Limited Company Background
| Sector | Healthcare |
|---|---|
| Activities | HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
| Latest Interim Date | 7 Aug 2025 |
| Latest Fiscal Year End Date | 19 Mar 2025 |
Hutchmed (China) Limited Directors
| Appointed | Name | Position |
|---|---|---|
| 2025-05-13 | Mr. Graeme Allan Jack | Non-Executive Director |
| 2025-10-21 | Mr. Dan Eldar | Non-Executive Director,Chairman |
| 2024-04-08 | Ms. Edith Shih | Non-Executive Director,Company Secretary |
| 2025-05-13 | Mr. Paul Rutherford Carter | Non-Executive Director,Senior Independent Director |
| 2017-02-01 | Mr. Christopher John Nash | Non-Executive Director |
| 2024-05-17 | Mr. Chi Keung Simon To | Executive Director,Chairman |
| 2022-03-03 | Mr. Christian Hogg | Executive Director,Chief Executive Officer |
| 2017-03-01 | Mr. Michael William Davis Howell | Non-Executive Director |
| 2017-02-01 | Professor Christopher Huang | Director |
| 2024-03-05 | Mr. Johnny Cheng Chig FUNG | Executive Director,Acting Chief Executive Officer and Chief Financial Officer |
| 2023-05-12 | Dr. Karen Jean Ferrante, M.D. | Non-Executive Director |
| 2025-08-26 | Dr. Weiguo Su | Executive Director,Chief Executive Officer and Chief Scientific Officer |
| 2025-10-21 | Professor Shu Kam Tony Mok | Non-Executive Director,Senior Independent Director |
| 2024-05-08 | Dr. Renu Bhatia | Non-Executive Director |
Hutchmed (China) Limited Contact Details
| Company Name | HUTCHMED (China) Ltd |
|---|---|
| Address | Ugland House, P.O. Box 309, Grand Cayman, KY1-1104 |
| Telephone | +852 21281188 |
| Website | https://www.hutch-med.com |
Hutchmed (China) Limited Advisors
| Financial PR Adviser | BMC Communications |
|---|---|
| Phone | +1 646 513-3125 |
| Financial PR Adviser | The Trout Group |
|---|---|
| Phone | +86 15821996861 |
| Fax | +86 16463782901 |
| Registrar | Computershare Investor Services Ltd |
|---|---|
| Phone | +44 8707074040 |
| Fax | +44 3708735851 |
| Auditor | PricewaterhouseCoopers |
|---|---|
| Phone | +852 22898888 |
| Fax | +852 28109888 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | UBS Limited |
|---|---|
| Phone | +44 2075678000 |
| Solicitor | DLA Piper LLP |
|---|---|
| Phone | +44 8700111111 |
| Fax | +44 2077966666 |
| Financial PR Adviser | Citigate Dewe Rogerson |
|---|---|
| Phone | +44 2076389571 |
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Itv PLC | 77.90 | 15.83 |
| Goodwin PLC | 22,400.00 | 3.23 |
| Oxford Nanopore Technologies PLC | 139.03 | 4.14 |
| Ceres Power Holdings PLC | 388.97 | 4.62 |
| Watches Of Switzerland Group PLC | 412.00 | 2.21 |
| Moonpig Group PLC | 209.75 | -0.59 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Rightmove PLC | 549.22 | -17.26 |
| International Consolidated Airlines Group S.A. | 377.80 | -11.15 |
| Me Group International PLC | 177.50 | -7.17 |
| Baltic Classifieds Group PLC | 270.50 | -6.08 |
| Auto Trader Group PLC | 751.20 | -5.27 |
| Metlen Energy & Metals PLC | 42.40 | -1.05 |